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ABSTRACT 
HUANCHEN WANG: Structural Studies On Substrate And Inhibitor Selectivity Of 
Phosphodiesterases 
(Under the direction of Dr. Hengming Ke) 
 
Cyclic nucleotide phosphodiesterases (PDEs) control the cellular concentration of 
“second messengers” adenosine or guanosine 3´, 5´-cyclic monophosphate (cAMP or 
cGMP). All PDEs contain a conserved catalytic domain, but each family possesses different 
substrate specificity and selective inhibitors. Selective inhibitors of PDEs have been studied 
as therapeutic agents for various diseases. However, many essential questions about the 
structure and function of PDEs remain mysteries. This dissertation will focus on inhibitor 
selectivity and substrate specificity studies of PDEs by X-ray crystallography, mutageneisis 
and enzymology. The crystal structure of PDE7 and kinetic analysis revealed multiple 
elements that jointly determinate inhibitor selectivity of PDEs. Crystal structures of PDE5 in 
complex with inhibitors showed multiple conformations of PDE5, providing insights into 
the enzyme function and for drug development. Crystal structures of PDE10 and structures 
of PDE4 subfamilies in complex with a PDE4D selective inhibitor will provide insights into 
the substrate specificity and subfamily inhibitor selectivity.  
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CHAPTER I 
INTRODUCTION OF FUNCTION AND STRUCTURE OF 
PHOSPHODIESTERASES 
1.1. Regulation of cellular concentration of cAMP and cGMP 
The second messengers cAMP and cGMP mediate the response of cells to a wide variety 
of hormones and neurotransmitters and modulate many metabolic processes, including 
cardiac and smooth muscle contraction, glycogenolysis, platelet aggregation, secretion, 
lipolysis, ion channel conductance, apoptosis, and growth control (1-7). Signaling of cAMP 
and cGMP in vivo is regulated mainly by three types of enzymes (Figure 1.1): cyclases, 
phosphodiesterases, and kinases. Intracellular cAMP and cGMP are synthesized by adenylyl 
cyclase (AC) and guanylyl cyclase (GC) in response to hormones and neurotransmitters (5, 8).  
The cyclic nucleotides activate cAMP/cGMP-dependent protein kinases (PKA and PKG) that 
in turn phosphorylate proteins downstream in the signaling pathways (9-11). Cyclic 
nucleotide phosphodiesterase (PDE) terminate the cAMP and cGMP signals by hydrolyzing 
the second messagers to 5´-AMP and 5’-GMP (Figure 1.2).  
 
1.2. Superfamily of PDEs 
PDEs comprise a large superfamily of enzymes. The 21 genes in human genome can be 
categorized into 11 families for their distinctive catalytic and regulatory properties, primary 
sequences, and sensitivities to PDE inhibitors. Alternative mRNA splicing of the 21 genes 
2generates over 60 isoforms of PDE in various human tissues (12-21). The PDE molecules can 
be divided into three regions: an N-terminal splicing region, a regulatory domain, and a 
catalytic domain near the C-terminus (Figure 1.3). The function of the N-terminal splicing 
region of the PDE families is unknown. The regulatory domains of PDEs contain various 
structural motifs and are assumed to play roles in the regulation of the catalytic activities of 
PDEs or in cross talk with other signaling pathways (21-23). Close at the C-terminus, a 
catalytic domain of about 300 amino acids conserve in all PDEs, but no homology is found in 
other regions. The catalytic domains share 65% or greater amino acid sequence identity in the 
same PDE family, whereas the amino acid identity drops to 40% or lower across families. 
 
Each PDE family has its individual substrate preference for cAMP and cGMP. Of the 11 
families of PDEs thus far identified, the PDE families 4, 7, and 8 prefer to hydrolyze cAMP 
while PDE5, 6 and 9 are cGMP specific. PDE1, 2, 3, 10 and 11 enzymes show activities 
toward both cAMP and cGMP (21) (Table 1.1). Thus, it has been a mystery how the similar 
active sites of PDEs distinguish the subtle differences between cAMP and cGMP (Figure 
1.2). 
 
1.3. PDE inhibitors as therapeutic agents  
The conservation of the catalytic domains would predict that members in the PDE 
families have common inhibitors. Indeed, several non-selective inhibitors of PDEs have been 
identified. For example, theophylline (Figure 1.4), a classical drug for treatment of asthma, is 
a non-selective PDE inhibitor (24, 25). On the other hand, each family of PDE possesses 
selective inhibitors that bind competitively to the conserved active site. For example, 
3roflumilast (Figure 1.4) is a PDE4 selective inhibitor with IC50 of 0.8 nM for PDE4 and IC50 
of 4 µM for PDE5 (26).  Sildenafil (ViagraTM, Figure 1.4) is a PDE5 selective inhibitor with 
IC50 of 3.5 nM for PDE5 and IC50 of 8 µM for PDE4 (17). It remains unclear how PDEs 
present selectivity on different inhibitors.  
 
In the past several decades, selective inhibitors of PDEs have been widely studied as 
therapeutics of cardiotonic agents, vasodilators, smooth muscle relaxants, antidepressants, 
antithrombotic compounds, antiasthma, and agents for improving cognitive functions such as 
learning and memory (27-36). Many PDE inhibitors have been tested in clinical trials or have 
already entered the marketplace. For example, vinpocetine, a PDE1 inhibitor, was tested for 
enhancing cognitive function and cerebrovascular health memory. The PDE3 selective 
inhibitor cilostazole (PletalTM, Figure 1.4) has been approved as a drug for reduction of 
symptoms of intermittent claudication. The PDE5 inhibitors sildenafil (ViagraTM, Figure 1.4), 
vardenafil (LevitraTM), and tadalafil (CialisTM) are drugs for treatment of male erectile 
dysfunction. Selective inhibitors of PDE4 form the largest group among any PDE families 
and have been studied as anti-inflammatory drugs for treatment of asthma and chronic 
obstructive pulmonary disease (COPD) and also as therapeutic agents against rheumatoid 
arthritis, multiple sclerosis, type II diabetes, septic shock, atopic dermatitis and other 
autoimmune diseases (32,37-42). Over 450 patents on PDE4 inhibitors have been published 
(40), but no PDE4 selective inhibitor has been approved for treatment of diseases.  PDE4 
inhibitors cilomilast and roflumilast (Figure 1.4) have shown their great potency for treatment 
of asthma and COPD (32, 39-42), but the side effects such as emesis at high dosage limit their 
practical application.  
4The side effects of the PDE inhibitors are generally thought to be the consequences of 
non-selective inhibition on other families or sub-families of PDEs. For example, the side 
effect headache of sildenafil presumably results from the non-selective binding of sildenafil 
to PDE4D or PDE1 in brain (17) and vision disturbance after administration of sildenafil may 
be due to the non-selective inhibition of sildenafil on PDE6 (43). Thus, improvement of the 
inhibitor selectivity is an essential step to enhance efficacy and to reduce side effects of the 
drugs. This is especially critical because over 60 isoforms of PDEs exist in human body.  
 
1.4. Structural studies on PDEs 
Since publication of the first crystal structure of the catalytic domain of PDE4B in 2000, 
structures of the catalytic domains of seven PDE families have been published: PDE1B (44), 
PDE2A (45), PDE3B (46), PDE4B and PDE4D (44, 47-54), PDE5A (44,52,55), PDE7A 
(56), and PDE9A (57), and a new crystal structure of PDE10A will be reported in this 
dissertation. In addition, the structures of a regulatory domain of PDE2A (58) and a fragment 
of PDE4D5 splicing region (59) have been reported. The catalytic domains of most PDE 
families contain sixteen -helices, fourteen of which are superimposable and thus define a 
conserved core (about 300 amino acids) of the catalytic domains for PDE families (Figures 5 
& 6). 
 
The structural studies have leaded a preliminary understanding on the hydrolysis 
mechanism, substrate specificity, and inhibitor selectivity. A mechanism by which PDE 
hydrolyzes cyclic nucleotides was proposed (51, Figure 7). In this model, the interactions of 
5cAMP phosphate with two metal ions polarize the phosphodiester bond so as to make the 
phosphorus atom partially positively charged. A water or hydroxide ion that bridges two 
metals is activated by Asp318 and attacks the phosphorus. His160 then serves as a proton 
donor for completion of the phosphodiester bond hydrolysis. This mechanism may be 
universal for all class I PDEs since the metal binding residues are highly conserved across all 
the PDE families.  
 
Structural studies have identified a conserved glutamine that plays a critical role in 
binding of substrates and inhibitor (46; 50-52). A “glutamine switch” mechanism has been 
proposed for differentiation of substrate specificity (44) on basis of the observation of that 
side chain of the invariant glutamine shows an opposite orientation in the crystals of PDE4 
and PDE5. In the structure of the PDE4D2-AMP complex, the orientation of the side chain 
(Residue Gln369) is fixed by a hydrogen bond with Tyr329 (Figure 1.8). In contrast, the 
orientation of the side chain (residue Gln817) is rotated about 180o and is fixed by Gln775 in 
the structure of the PDE5A1-GMP complex. The “glutamine switch” mechanism assumes a 
free rotation of the invariant glutamine in the PDE families that have dual specificity. 
However, the recently structure of PDE2A showed that Gln859 already forms a hydrogen 
bond with Tyr827 (45). Thus, the mechanism of “glutamine switch” need further studies. 
 
A large number of the crystal structures of PDE in complex with both non-selective and 
selective inhibitor identified a common binding pattern for all PDE inhibitors: stacking 
against a conserved phenylalanine and forming a hydrogen bond network with a conserved 
glutamine. These two factors probably form a core of a common subpocket for binding of all 
6inhibitors. However, it remains unknown what are determinants for selective binding of 
structural distinct inhibitors in different PDE families and if each PDE family has its 
characteristic combination of recognition elements or shares certain elements with other PDE 
families. 
 
1.5. Focus of this dissertation 
Working in Dr. Ke’s lab, I have focused on the issues of substrate specificity and 
inhibitor selectivity of PDEs by X-ray crystallography and enzymatic approaches. In this 
dissertation, I  will report crystal structures of PDE7 and the kinetic analysis on the mutants of 
PDE4 and PDE7, to address the issue of inhbitor selectivity in these PDE families in chapter 
II. In chapter III, I will describe the crystal structures of PDE5 in the unliganded form and in 
complex with inhibitors sildenafil and icarid II and discuss multiple conformations of PDE5 
and the implication on the enzyme function and drug development. In chapeter IV I will 
report the recently progress on expression, purification, and structural determination of PDE 
PDE4A, PDE4B, PDE4C, PDE4D, and PDE10A. Finally, I will list and attach the reprints of 
other works that I contributed to during my PhD studies, including the crystal structures of 
PDE4D in complex with enantiomer inhibitors, rolipram, PDE9 in complex with IBMX, 
DJ-1, E. Coli Hsp90. and a complex involving a mouse TCR and a human MHC molecule. 
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Figure 1.1. Signal pathway of cAMP and cGMP. The second messengers cAMP and cGMP 
are synthesized by adenyl or quanyl cyclases and hydrolyzed by phosphodiesterases, and 
activate protein kinases for regulation of biological processes. 
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Figure 1.2. Catalysis by cyclic nucleotide phosphodiesterases.  
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Figure 1.3. Domain structures of the eleven PDE families. PDE nomenclature has been made 
as the following example: PDE4D2 is defined as family 4, D gene or subfamily D, isoform 2).                   
C Calmodulin binding domain,              Catalytic domain,            GAF (cGMP specific PDE, 
Adenylyl cyclase, and Fh1A) domain,            probable transmembrane domain,               
Upstream conserved region,                 PAS (Period clock protein, Aryl hydrocarbon receptor 
nuclear translocator, and Single-minded protein) domain. 
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Figure 1.4. Chemical structures of PDE inhibitors. Vinpocetine is a PDE1 selective inhibitor. 
Cilostazol is a PDE3 selective inhibitor. Rolipram, roflumilast, cilomilast are PDE4-selective 
inhibitors. Sildenafil, tadalafil, vardenafil are PDE5-selective inhibitors. Theophylline and 
IBMX are non-selective inhibitors for all PDEs. 
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Figure 1.5. Structure of the PDE4D2 catalytic domain.  (A) Ribbon diagram. Alpha-helices 
are shown in cyan and 310 helices are in blue. Rolipram is represented by the golden 
ball-sticks. (B) Surface presentation of PDE4D2 catalytic domain. Red color represents 
negatively charged oxygen and blue is for nitrogen. The golden balls are atoms of rolipram. 
 
(A)       (B) 
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Figure 1.6. Second structure alignment of eight PDE catalytic domains on the basis of three 
dimensional structures. The unliganded PDE5 is used in the alignment. 
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Figure 1.7. A putative mechanism for the phosphodiester bond hydrolysis by PDEs (51).  
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Figure 1.8. The hydrogen bonding network for binding of the nucleotides at the active site of 
PDE4 and 5. The AMP (cyan bonds) and GMP (golden bonds) were modeled on basis of the 
superposition of the crystal structures over PDE4D-AMP or PDE5A-GMP.  
 
(PDE4D2)    (PDE5A1) 
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Table 1.1. Kinetics properties of PDEs (20). 
 cAMP (KM µM) cGMP (KM µM)
PDE1 1-30 3 
PDE2 30-100 10-30 
PDE3 0.1-0.5 0.1-0.5 
PDE4 0.5-4 >50 
PDE5 >40 1.5 
PDE6 2000 60 
PDE7 0.2 >1000 
PDE8 0.7 >100 
PDE9 >100 0.07 
PDE10 0.05 3 
PDE11 1 0.5 
CHAPTER II 
MULTIPLE ELEMENTS JOINTLY DETERMINE INHIBITOR SELECTIVITY OF 
CYCLIC NUCLEOTIDE PHOSPHODIESTERASES 4 AND 7 
 
2.1. Abstract 
Phosphodiesterase (PDE) inhibitors have been widely studied as therapeutics for 
treatment of human diseases. However, the mechanism by which each PDE family recognizes 
selectively a category of inhibitors remains a puzzle. In this chapter I will report the crystal 
structure of PDE7A1 catalytic domain in complex with non-selective inhibitor 
3-isobutyl-1-methylxanthine and kinetic analysis on the mutants of PDE7A1 and PDE4D2. 
The structural study suggests at least three elements play critical roles in inhibitor selectivity: 
1) the conformation and position of an invariant glutamine, 2) the natures of scaffolding 
residues, and 3) residues that alter shape and size of the binding pocket. Kinetic analysis 
shows that the single PDE7 to PDE4 mutations increase the sensitivity of PDE7 to PDE4 
inhibitors by a few fold, but are not sufficient to render the engineered enzymes comparable 
with the wild types. The triple S373Y/S377T/I412S mutation of PDE7A1 produces a 
PDE4-like enzyme, implying that multiple elements must work together to determine 
inhibitor selectivity. 
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2.2. Introduction 
Phosphodiesterase family 7 (PDE7) consists of two genes, PDE7A and PDE7B. 
Alternative RNA splicing of PDE7 genes generates PDE7A1 (482 amino acids), PDE7A2 
(456 aa), PDE7A3 (425 aa), PDE7B1 (450 aa), and PDE7B2 (583 aa).  PDE7 is abundantly 
expressed in immune cells and has been implicated in T lymphocyte activation (1-5), 
although there is a report that PDE7A knockout mice showed no deficiency in T cell 
proliferation (6). Like PDE4, PDE7 prefers to hydrolyze cAMP with a KM value of 0.03 to 0.2 
µM (7-11). However, PDE7 is not sensitive to PDE4 inhibitors such as rolipram (Figure 2.1), 
and thus was originally named as “rolipram-insensitive PDE family”. To understand the 
inhibitor selectivity of the PDE7 and PDE4 families, I have determined the crystal structure of 
the PDE7A1 catalytic domain in complex with 3-isobuty-1-methylxanthine (IBMX) and 
performed mutagenesis on PDE7A1 and PDE4D2. These studies show that several key 
residues must work together to switch the inhibitor selectivity between PDE4 and PDE7, and 
thus provide a valuable insight into selectivity of PDE inhibitors. The results have been 
published in Journal of Biological Chemistry (12). 
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2.3. Experimental procedures 
Subcloning, protein expression and purification-- The cDNA of PDE7A1 was purchased 
from American Type Culture Collection (ATCC, BE782968) and subcloned into the vector 
pET32a-W following the standard protocols. The S·tag and enterokinase site in the 
commercial pET32a were deleted to generate the modified vector pET32a-W. A pair of 
oligonucleotide primers of GCCTGGATCCTCAAATTCCCTAAAC and CGCGCTCGAG- 
TTATGATAACCGATTTTC was synthesized for amplification of the PDE7A1 coding 
region of amino acids 130-482 by PCR. The amplified PDE7A1 DNA and the expression 
vector pET32a-W were separately digested by the restriction enzymes BamHI and XhoI, 
purified from agarose gel, and then ligated by T4 DNA ligase. The plasmid pET32- PDE7A1 
(130-482) was transferred into E. coli strain BL21 (codonplus) for overexpression. The E. 
coli cell carrying pET-PDE7A1 was grown in 2xYT medium at 37oC to absorption A600 = 
1.0 and then 0.1 mM isopropyl -D-thiogalactopyranoside was added for further growth at 
15oC for 12-16 hours. The cells were harvested and frozen at -80 oC for use. 
 
The catalytic domain of PDE7A1 was purified with three chromatographic columns of 
Ni-NTA (Qiagen), Q-sepharose (Amersham Biosciences), and Sephacryl S300 (Amersham 
Biosciences). The Ni-NTA affinity column was washed with a buffer of 20 mM Tris.base, pH 
8.0, 300 mM NaCl, 15 mM imidazole and 1 mM -mercaptoethanol, and PDE7A1 was eluted 
out with a buffer of 20 mM Tris.base, pH 8.0, 50 mM NaCl, 150 mM imidazole, and 1 mM 
-mercaptoethanol. After removal of the His-tag by thrombin cleavage, the PDE7A1 catalytic 
domain was loaded into Q-sepharose column, washed with 20 mM Tris.base, pH 7.5, 100 
mM NaCl, 1 mM -ME, 1 mM MgCl2, and 10% glycerol, and eluted out with a similar buffer 
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but 200 mM NaCl. The PDE7A1 was finally purified by passing through Sephacryl S300 
column in a buffer of 20 mM Tris.base, pH 7.5, 50 mM NaCl , 1 mM -mercaptoethanol, and 
1 mM MgCl2. A typical batch of purification yielded about 5 mg PDE7A1 from 4 liters of cell 
culture. The purified protein showed a single band in SDS PAGE and native PAGE and is 
estimated to have purity of better than 95% (Figure 2.2). The purified catalytic domain of 
PDE7A1 was concentrated to 5 mg/ml and stored at -80 oC for use.  
 
The cDNA clone of full-length PDE4D2 was purchased from American Type Culture 
Collection (BF697394) and subcloned into pET15b. The plasmid pET- PDE4D2 (1-507) was 
transferred into E. coli strain BL21 (codonplus) for overexpression. The E. coli cell carrying 
pET-PDE4D2 was grown in LB medium at 37oC to absorption A600 = 0.7 and then 0.1 mM 
isopropyl -D-thiogalactopyranoside was added for further growth at 15oC for 20 hours. The 
cells were harvested and frozen at -80 oC. The full-length PDE4D2 (1-507) was purified with 
three chromatographic columns of Ni-NTA (Qiagen), Q-sepharose (Amersham Biosciences), 
and Sephacryl S300 (Amersham Biosciences). The Ni-NTA affinity column was washed with 
a buffer of 20 mM Tris.base, pH 8.0, 300 mM NaCl, 15 mM imidazole and 1 mM 
-mercaptoethanol, and eluted with similar buffer but 50 mM NaCl and 150 mM imidazole. 
After removal of the His-tag by thrombin digestion, the full-length PDE4D2 was loaded into 
Q-sepharose column, washed with 20 mM Tris.base, pH 7.5, 200 mM NaCl, 1 mM -ME, 1 
mM EDTA, and 10% glycerol, and eluted out with a similar buffer but 300 mM NaCl. The 
PDE4D2 was finally purified by passing through Sephacryl S300 column in a buffer of 20 
mM Tris.base, pH 7.5, 50 mM NaCl, 1 mM -mercaptoethanol, and 1 mM EDTA. A typical 
batch of purification yielded about 20 mg PDE4D2 from 2 liters of cell culture. The purified 
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protein showed a single band in SDS PAGE and native PAGE and is estimated to have purity 
of better than 95% (Figure 2.2).  
 
The mutants of PDE4D2-(1-507) and PDE7A1-(130-482) were produced with a 
QuikChangeTM site-directed mutagenesis kit and verified by DNA sequencing. The primers 
for PCR of the mutation are listed in Table 2.1. 
 
All mutants were overexpressed in BL21 (codonplus) and purified using the same 
procedure as that for the wild types. The expression levels of the PDE7A1 mutants are 
comparable with that of the wild type PDE7A1. The purified PDE7A1 mutants are estimated 
to have purity >95% as shown by the SDS gel (Figure 2.2). 
Crystallization and structure determination -- Crystals of PDE7A1-IBMX were grown 
by vapor diffusion. The catalytic domain of 5 mg/mL PDE7A1 (amino acids 130-482) in a 
storage buffer of 50 mM NaCl, 20 mM TrisHCl (pH 7.5), 1 mM Z-mercaptoethanol, and 1 
mM EDTA was mixed with 1 mM IBMX, and crystallized by hanging drop at 4oC. The 
protein drops contained 2 µl PDE7A1-IBMX and 2 µl well buffer of buffer 0.6 - 0.8 M 
(NH4)2SO4, 2.5 - 5 mM Z-mercaptoethanol, 10 mM EDTA, 0.1 M TrisHCl, pH 7.5. The well 
buffer plus 20% glycerol was used as the cryo-solvent for freezing the crystals in liquid 
nitrogen. Diffraction data were collected on beamline X29 of National Synchrotron Light 
Source. The PDE7A1-IBMX crystal has the space group P3121 with cell dimensions of a = 
115.8, and c = 64.3 Å. The diffraction images were automatically indexed and integrated by 
the subroutine Denzo of HKL, and then all the images were scaled and reduced by subroutine 
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Scalepack of HKL(13). The statistics on the data process are shown in Table 2.2. The 
structure of PDE7A1-IBMX was solved by molecular replacement program AMoRe (14), 
using the catalytic domain of PDE4D2 as the initial model (15). The structure determination 
by AMoRe includes two steps: rotation function and translation search. The rotation function 
of AMoRe produced a peak with correlation coefficient of 0.12 for 3795 reflections at 4-8 Å 
resolution, which is about 6 times the remaining solutions. A further search of the peak by the 
translation function of AMoRe yielded a correlation coefficient of 0.73 and R-factor of 0.31 
for 3795 reflections at 4-8 Å resolution. The phases from the molecular replacement were 
improved by the density modification package of program CCP4 (16). The atomic model 
output from AMoRe was displayed in a Silicon graphic system and amino acid differences 
between PDE4 and PDE7 and residue positions were built by program O (17) for the best fit 
to the electron density maps. The structure was refined by program CNS (Crystallography and 
NMR System, 18).  
 
Assay of phosphodiesterase activities--The enzymatic activities of the catalytic domains 
of PDE7A1-(130-482) and full-length PDE4D2-(1-507) and their mutants were assayed by 
incubating the enzymes with 100 \l reaction mixture of 50 mM Tris·HCl (pH 8.5), 50 mM 
MgCl2, 5 mM dithiothreitol,, and 3H-cAMP or 3H-cGMP (30,000 cpm per assay, 
Sigma-Aldrich) at room temperature for 10 min. The reactions were terminated by addition of 
200 \l 0.2 M ZnSO4 when 20%-35% of cAMP or cGMP was hydrolyzed. The reaction 
product 3H-AMP or 3H-GMP was precipitated by addition of 200 \l 0.25 M Ba(OH)2
(Sigma-Aldrich), while unreacted 3H-cAMP or 3H-cGMP remained in the supernatant. 
Radioactivity of the supernatant was measured in 3.5 ml liquid scintillation cocktails 
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(ScintiSafe PlusTM 50%, Fisher Scientific) by a LKB RackBeta 1214 counter. The activity 
was measured at nine concentrations of cAMP or cGMP and each measurement was repeated 
three times. Vmax and KM values were calculated by the linear plots of Lineweaver–Burk and 
Eadie-Hofstee (Figure 2.3).  Protein concentrations were calculated from the extinction 
coefficients at O.D. 280 nm, which were calculated by program ProtoParam (ExPASy). For 
measurement of inhibition, 10-12 concentrations of inhibitors were used under the substrate 
concentration of one tenth of KM and the enzyme concentration range of 10-300 ng/ml. The 
enzyme concentration that hydrolyzes 50% of the substrate was chosen for each inhibition 
assay of mutants. The hydrolysis rate has a linear relationship with the enzyme concentration 
and time until 65% substrate has been converted to product. Each experiment was repeated 
two or three times.  The IC50 values are the concentration of inhibitors when 50% activities of 
the enzymes are inhibited. 
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2.4. Results 
Kinetic properties -- The catalytic domain of PDE7A1 has a KM value of 0.2 ± 0.03 µM
and a kcat value of 1.6 ± 0.2 s-1 for cAMP (Figure 2.3), in contrast to a KM of 3.9 ± 0.7 mM and 
a kcat of 6.8 ± 1.3 s-1 for cGMP (Table 2.3). The ratio of the specificity constants 
(kcat/KM)cAMP/(kcat/KM)cGMP is about 4,000.  The full length PDE4D2 has KM of 1.5 ± 0.2 µM
and kcat of 3.9 ± 0.3 s-1 for cAMP and KM of 1.0 ± 0.1 mM and kcat of 5.2 ± 0.8 s-1 for cGMP. 
The ratio of the specificity constants (kcat/KM)cAMP/(kcat/KM)cGMP is about 500. Thus, these 
specific constants confirm that PDE7A1 and PDE4D2 are cAMP specific. The  kcat value of 
our PDE7A1 catalytic domain is about 5 times that of PDE7A1 refolded from the inclusion 
bodies (11) and about half that of PDE4D2, suggesting that the purified PDE7A1 catalytic 
domain has a native-like folding. It is interesting to note that both PDE4D2 and PDE7A1 have 
similar kcat values for cAMP and cGMP. However, the KM values for cGMP are about 700 and 
2000 fold bigger than those for cAMP, thus implicating that KM is the dominant factor for 
substrate specificity. 
 
Overall structure of PDE7 -- The catalytic domain of PDE7A1 (residues 130-482) 
contains 17 -helices (Figure 2.4) and has the same topology of folding as do other PDEs (15, 
19-28). Two divalent metals were tentatively interpreted as Zn and Mg for the purpose of 
structure refinement. Residues 130-138 and 458-482 were not traceable in the structure due to 
lack of electron density. The N-terminal fragments of the catalytic domains in the PDE 
families (130-157 in PDE7A1) do not have comparable amino acid sequences and vary in 
their secondary structure elements. Among them, PDE4B, PDE4D, and PDE1B (15, 19, 26) 
contain helices H1 and H2 have a similar folding; PDE3B (28) shows only a comparable helix 
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H2; and PDE5 and PDE9 have different secondary and tertiary structures for their N-terminal 
residues (24,25). The catalytic domain of PDE7A1 resembles PDE4 mostly and their entire 
catalytic domains are comparable, as shown by an average difference of 0.93 Å for the 
superposition of C atoms of PDE7A1 residues 139-455 on the equivalents of PDE4D2. 
However, minor differences are observed between PDE7A1 and PDE4D2. First, PDE7A1 has 
two deletions around residues 297 and 341 (Figure 2.4C). Second, two 310 helices (a type of 
helix involving 3 residues/turn) in PDE4D2 appear as -helices in PDE7A1 (He and H10, 
Figure 2.4C) and a 310 helix in PDE4D2 (residues 98-102) becomes a coil in PDE7A1. The 
most significant change is associated with the N-terminal portion of helix H11 (residues 
304-310 of PDE7A1), which shows an average positional movement of 2.8 Å, about ~3 times 
the overall average of 0.93 Å for the whole catalytic domain. This structural change appears to 
be statistically meaningful, but the biological significance is not clear. The positional change 
of helix H11 may either reflect intrinsic conformation variation between PDE4 and PDE7 or 
may be due to the tetramer formation in the PDE4D2 crystal, because H11 contributes a small 
portion of the interface of the PDE4D2 tetramer but is not involved in lattice packing in 
PDE7A1. 
IBMX binds to a subpocket common for all PDE inhibitors -- IBMX (Figure 2.1) is a 
non-selective inhibitor for most PDEs and shows IC50 of 2-9 µM for PDE7A and PDE7B (5, 9, 
10). The catalytic domain of PDE7A1 has an IC50 of 8.1 ± 0.4 µM for IBMX, thus implying 
that the binding determinants are located within the catalytic domain of PDE7. This argument 
is supported by the crystal structure of PDE7A1, in which IBMX occupies the bottom of the 
deep pocket and is not exposed at the surface of the catalytic domain. The xanthine ring of 
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IBMX stacks against Phe416 (Figure 2.5, Table 2.4) and its oxygen O6 forms a hydrogen 
bond with Gln413 (Figure 2.5, Table 2.4). It also contacts PDE7A1 residues Tyr211, Val380, 
and Phe384 via van der Waals’ interactions (Figure 2.5, Table 2.4). Two water molecules 
bound to O2 and N7 of xanthine, respectively (Table 2.4). The isopropanyl group of IBMX 
interacts with residues Phe384, Ile412, and Phe416 (Figure 2.5, Table 2.4). The above 
interactions of IBMX with PDE7A1 are similar to those in other PDEs (24,25). Overall, 
IBMX shows conservation of stacking against phenylalanine and a hydrogen bond to the 
invariant glutamine in all the PDE families. However, IBMX shows significant positional 
shifts among PDE4, 5, 7, and 9. For example, IBMX in PDE7A1 has an average positional 
shift of about 1.3 Å from that in PDE4D2. This may reflect that the large pockets in PDEs 
allow orientational variation of IBMX, as long as the stacking and the hydrogen bond are 
conserved. Based on the crystal structures of PDE4, 5, 7 and 9 in complex with IBMX, the 
hydrogen bond with the invariant glutamine and stacking against the phenylalanine appear to 
be two key components for common binding of all PDE inhibitors (24, 25). This argument is 
supported by the studies on the structures of PDE4 and PDE5 in complex with various 
inhibitors (27).  
 
Insensitivity of PDE7 to PDE4 inhibitors -- Rolipram and its derivatives RO-20-1724 
and zardaverine do not significantly inhibit the catalytic domain of the wild-type PDE7A1 
(Table 2.5), consistent with reports in the literature (9, 10). PDE7A1 is more sensitive to 
inhibition by etazolate than by other PDE4 inhibitors, perhaps because etazolate has a 
structure similar to non-selective inhibitor IBMX (Figure 2.1).  
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The inhibitor sensitivity can be explained on the basis of the crystal structures of 
PDE4D2-rolipram and PDE7A1-IBMX. The structure of PDE4D2-rolipram showed that the 
rolipram binding in PDE4 is stabilized by two hydrogen bonds with the invariant glutamine 
Gln369, whose conformation is fixed by the hydrogen bond to Tyr329 (15, 20, 27). In 
PDE7A1, the invariant glutamine Gln413 does not form a hydrogen bond with the Tyr329 
equivalent, Ser373, but with Ser377. The structural superposition between the catalytic 
domains of PDE7A1 and PDE4D2 shows that Gln413 in PDE7A1 exhibits the same side 
chain conformation as that of Gln369 in PDE4D2 with an average positional shift of 1.1 Å 
(Figure 2.5C). This positional change is slightly higher than the average difference of 0.93 Å 
between PDE7A1 and PDE4D2, but is about twice those of other active site residues (e. g. 
0.56 Å for Ser373/Tyr329). Thus, the conformation and positioning of the glutamine side 
chain and the scaffolding residues must be the factors for recognition of inhibitors. On the 
other hand, Ile412 of PDE7A1, which neighbors on Gln413, has a positional shift of 1.6 Å 
from its corresponding partner Ser368 in PDE4D2, almost twice the overall average 
difference. The positional change and variation of amino acid type make a different size and 
shape of the binding pocket in PDE7A1 from PDE4D2 (Figures 5D and 5E), so that Ile412 
may be the third factor for inhibitor selectivity. In fact, modeling of rolipram into PDE7A1 on 
the basis of the structural superposition shows that the side chain of Ile412 is located less than 
1 Å from the cyclopentanyl group of rolipram (Figure 2.5C), indicating that it sterically 
hinders the binding of rolipram. In summary, the PDE7 structure suggests that at least three 
factors play roles in inhibitor selectivity: (1) the conformation and positioning of the invariant 
glutamine (Gln413 in PDE7A1), (2) residues scaffolding the glutamine such as Tyr329 in 
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PDE4D2 and Ser377 in PDE7A1, and (3) residues affecting the shape and size of the binding 
pockets such as Ile412 in PDE7A1.  
 
Multiple determinants for inhibitor selectivity -- To further understand the inhibitor 
selectivity in PDE4 and PDE7, kinetic analysis was carried out on the mutations on residues 
Ser373, Ser377, and Ile412 of PDE7A1, and Tyr329 of PDE4D2. Single mutations of the 
PDE7A1 residues to the equivalents of PDE4D2 showed decrease of the IC50 values by 2-3 
fold for rolipram (Table 2.5, Figure 2.6). Because the changes of IC50 values are at least 8-fold 
that the experimental errors (Table 2.5), the sensitivity increase of the mutants to rolipram 
inhibition is statistically significant. The double PDE7/4 mutations reduced the IC50 values 
for rolipram by 4-6 fold (Figure 2.6, Table 2.5). The most dramatic change is the 
S373Y/S377T/I412S triple mutation that showed IC50 of 3.2 µM for (R, S)-rolipram, kcat of 
2.7 s-1, and KM of 2.2 µM for cAMP. All of the three kinetic parameters are very close to 0.55, 
3.9, and 1.5 for the wild type PDE4D2, respectively. 
 
Consistently, the PDE7A1 mutants showed increases of the sensitivity to the other PDE4 
inhibitors (Table 2.5). RO-20-1724 had IC50 of 245 µM for the wild type PDE7A1, but the 
IC50 values of the single mutants were reduced by 2-9 fold. The triple mutation exhibited IC50 
of 5.5 µM, only about 2 times higher than 2.9 µM for the wild type PDE4D2. The dual 
PDE3/4 inhibitor zardaverine showed the IC50 values of 75 µM for wild type PDE7A1, 1.0 
µM for wild type PDE4D2, and 2.3 µM for the triple mutant of PDE7A1 (Table 2.5). The 
insensitivity of zardaverine to the I412S mutant of PDE7A1 probably is due to the small 
fluoride group.  
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To see whether introduction of a PDE7 residue to PDE4 could make a PDE7-like 
enzyme, we examine the Y329S mutant of PDE4D2. This single mutation of PDE4D2 
resulted in 2-75-fold loss in sensitivity to the PDE4 inhibitors (Figure 2.7, Table 2.5), 
confirming the importance of the tyrosine residue as the scaffold and also cross-verifying the 
effects observed in the PDE7A1 mutants. In short, the kinetic data suggest that the three 
residues must work together to significantly change the inhibitor selectivity. 
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2.5. Discussion 
Extensive structural studies have shed light on the substrate specificity and inhibitor 
selectivity of PDEs (15, 19-28). The structures of PDE4 in complex with rolipram (15, 20, 27) 
showed that an invariant glutamine (Glu369 in PDE4D2) forms two hydrogen bonds with 
rolipram, implying a critical role of the glutamine in inhibitor binding. On the other hand, the 
opposite orientation of the side chain of the glutamine in the PDE4 and PDE5 structures (24, 
26) also suggest a key role of the glutamine in substrate specificity. Comparison of the 
structures of PDE4, PDE5, and PDE9 in complex with IBMX leads to identification of a 
common pocket for non-selective binding for all PDE inhibitors (24, 25). The structures of 
PDE4 and PDE5 in complex with various selective inhibitors support the proposal of the 
common pocket and identify other subpockets that are important for inhibitor binding (27). 
The structural and kinetic studies on the mutants in this report quantitatively show the role of 
several residues, thus a further insight into the inhibitor selectivity. 
 
PDE7 was originally named as a family of “rolipram insensitive PDE”, but it has 
remained unknown why PDE7 is not sensitive to PDE4 inhibitors. To explain the poor 
inhibition of PDE7 activity by PDE4 inhibitors, a rolipram-recognition triad (Tyr329, Thr333, 
and Gln369 in PDE4D2, or Ser373, Ser377, and Gln413 in PDE7A1) was proposed on basis 
of the crystal structures of PDE4D2 in complex with rolipram(15). The side chain 
conformation of invariant Gln369 is stabilized by a hydrogen bond to Tyr329 in PDE4. It was 
also predicted that the replacement of Tyr329 with Ser373 in PDE7A1 would switch the side 
chain of Gln413 away from Ser373 to form a hydrogen bond with Ser377, thus demolishing 
the hydrogen bonds between the glutamine and rolipram (15). The PDE7A1-IBMX structure 
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reveals the hydrogen bond between Gln413 and Ser377, confirming the earlier prediction (15). 
However, the invariant glutamine (Gln413 in PDE7A1) does not change its side chain 
conformation but its position, thus suggesting that the positioning of the glutamine is critical 
for inhibitor binding. In addition, my study shows that two groups of residues are critical for 
the inhibitor selectivity. One is the scaffolding residues such as Tyr329 in PDE4D2 and 
Ser377 in PDE7A1, which support the conformation and position of the invariant glutamine. 
Another is residues such as Ile412 in PDE7A1 that affect the shape and size of the binding 
pocket. 
 
The significant change of the inhibitor sensitivity by the single mutations of PDE7A1 
and PDE4D2 can be explained on a structural basis. The S373Y mutation in PDE7A1 may 
add a PDE4-like hydrogen bond network between the mutated Tyr373 and Gln413, thus 
placing the glutamine in a favorable position for formation of hydrogen bonds with rolipram 
(Figure 2.5C). Similarly, the Y329S mutation in PDE4D2 will release Gln369 from the 
hydrogen bond and thus disfavor its interaction with rolipram. Although the S377T mutation 
in PDE7A1 is relatively conserved, modeling of the torsion angles of the threonine shows that 
C of Thr377 blocks its formation of a hydrogen bond with Gln413 so as to release Gln413 for 
interaction with rolipram. The I412S mutation in PDE7A1 apparently makes room for 
binding of rolipram and avoids of steric clash (Figure 2.5B). Although the single mutations 
change the inhibitor sensitivity significantly, none of them produces an engineered enzyme 
comparable with the wild types. The PDE4D-like behavior of the triple mutant of PDE7A1 
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suggests that the multiple components must work together to determine the inhibitor 
selectivity.  
 
The studies in this report provide clues for design of selective inhibitors against PDE4 or 
PDE7. The subpocket occupied by the cyclopentanyl group of rolipram in PDE4 is filled with 
or closed up by Ile412 in PDE7. Therefore, the cyclopentanyl group of rolipram or a similar 
group in a PDE4 selective inhibitor can be designed to occupy this subpocket. In comparison, 
PDE7 selective inhibitors must have a small group for this pocket to avoid of any clashes. 
Since both the conformation and position of the invariant glutamine are important for 
inhibitor binding, a dual-selective inhibitor targeting both PDE4 and PDE7 can be designed 
by forming hydrogen bonds with the glutamine and stacking against Phe372 in PDE4 or 
Phe416 in PDE7.   
 
Although each PDE family may have its characteristic components for inhibitor 
recognition, the three elements (an invariant glutamine, scaffolding residues, and residues 
affecting the pocket) would play essential roles in inhibitor recognition in all PDE families 
because of its conservation and critical location. Therefore, the understanding on the inhibitor 
selectivity of PDE4 and PDE7 would provide a general guideline for design of highly 
selective inhibitors of PDE families. 
 
36
FOOTNOTES 
The atomic coordinates and structure factors (code 1ZKL) have been deposited in the 
Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, 
New Brunswick, NJ (http://www.rcsb.org/). 
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Figure 2.1. Chemical structures of PDE inhibitors. 
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Figure 2.2.  The 15% SDS acrylamide gel on the purified proteins. The wild type and mutant 
Y329S of PDE4D2 are shown in lanes 1 and 2, respectively. The remaining lanes are for 
PDE7A1 (130-482): wild type (lane 3), S373Y (lane 4), S377T (lane 5), I412S (lane 6), 
S373Y/S377T (lane 7), S373Y/I412S (lane 8), S377T/I412S (lane 9) and 
S373Y/S377T/S412S (lane 10). 
 
.
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Figure 2.3. PDE7 kinetic. (A)The Lineweaver–Burk plot. The calculated KM is 0.18 µM, 
Vmax is 2.19 µmol/min/mg.  (B) The Eadie-Hofstee plot. The calculated KM is 0.20 µM, 
Vmax is 2.3 µmol/min/mg. The plots represent the mean of three experiments. 
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Figure 2.4. PDE structures. (A) Ribbon diagram of PDE7A1 catalytic domain, IBMX is 
shown as green balls. Two metals are labeled as Zn and Mg. (B) Ribbons of PDE4D2 catalytic 
domain. Rolipram is shown as golden balls.  
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Figure 2.4. (C) The alignment of secondary structure and sequence between PDE7A1 and 
PDE4D2. The three residues that have been mutated are highlighted with yellow. 
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Figure 2.5. The inhibitor binding. (A) Stereo view of electron density for IBMX. The 
(2Fo-Fc) map was calculated from the structure with omission of IBMX and contoured at 1_.
(B) IBMX (golden sticks-balls) binding to the active site of PDE7A1 catalytic domain. The 
hydrogen bonds are represented by dotted lines. (C) Superposition of rolipram-binding 
residues of PDE4D2 (cyan sticks and blue labels) over those of PDE7A1 (green sticks and red 
labels). The cyclopentanyl ring of rolipram will clash with the side chain of Ile412 if Gln413 
forms hydrogen bonds with the oxygen atoms of phenylmethoxy of rolipram. (D) Surface 
presentation of the subpocket for the cyclopentanyl group of rolipram in PDE4D2. (E) 
Surface presentation for the same binding pocket in PDE7A1. It is visible that the size and 
shape of the subpocket for the cyclopentanyl group are different. 
45
 
Figure 2.5. 
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Figure 2.6. Inhibition on the cAMP activity of the catalytic domain of the wild type PDE7A1 
and its mutants by PDE4 inhibitors: (R, S)-rolipram, RO-20-1724, zardaverine, and etazolate. 
The error bars were calculated from two or three times of repeated measurement. 
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Figure 2.7. Inhibition on the cAMP activity of the wild type PDE4D2 and its Y329S mutant 
by PDE4 inhibitors: (R, S)-rolipram, RO-20-1724, zardaverine, and etazolate. The error bars 
were calculated from two or three times of repeated measurement. 
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Table 2.1. Primers for mutations of PDE4 and PDE7. 
Mutants* Primers 
PDE7A1-S373Y        5’-CCATGTCGGACGTGGGAGCTCTACAAGCAGTGGAGTGAAAAAG and 
 3’-CTTTTTCACTCCACTGCTTGTAGAGCTCCCACGTCCGACATGG 
PDE7A1-S373Y/S377T** 5’-GTCGGACGTGGGAGCTTTACAAGCAGTGGACTGAAAAAGTAACGGAGG 
3’-CCTCCGTTACTTTTTCAGTCCACTGCTTGTAAAGCTCCCACGTCCGAC 
PDE7A1-S377T        5’-CCATGTCGGACGTGGGAGCTCTCCAAGCAGTGGACTGAAAAAGTAACG 
3’-CGTTACTTTTTCAGTCCACTGCTTGGAGAGCTCCCACGTCCGACATGG 
PDE7A1-I412S        5’-CACACTGAATCTATTGCGAATTCCCAGATTGGTTTTATGAC 
3’-GTCATAAAACCAATCTGGGAATTCGCAATAGATTCAGTGTG  
PDE4D2-Y329S        5’-CAACAAAGCCTCTCCAGCTGAGCCGCCAGTGGACGGACC 
 3’-GGTCCGTCCACTGGCGGCTCAGCTGGAGAGGCTTTGTTG 
*For other mutants, PDE7A1-S373Y/I412S, PDE7A1-S377T/I412S and PDE7A1-S373Y/- 
S377T/I412S were generated from PDE7A1-S373Y, PDE7A1-S377T and PDE7A1- 
S373Y/S3777T using primers of PDE7A1-I412S, respectively.  
** Generated from PDE7A1-S373Y. 
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Table 2.2. Statistics on diffraction data and structure refinement. 
 
Data collection  PDE7A1-IBMX    
Space group   P3121      
Unit cell (a, b, c, Å)  115.8, 115.8, 64.3    
Resolution (Å)   50-1.67 (1.73-1.67) 
Total measurements  410,779 
Unique reflections    57,579 
Completeness (%)  99.6 (96.2)*     
Average I/ 13.2 (2.5)*     
Rmerge   0.071 (0.48)*    
 
Structure Refinement 
Resolution (Å)   50-1.67 
Reflections   55,766    
R-factor/R-free  0.194/0.207     
 
Number of atoms 
 Protein   2596 
 IBMX   16 
 Waters   289 
 Zn   1 
 Mg   1 
Average B-factor (Å2)
Protein   20.9 
 IBMX    25.0 
 Waters   32.7 
 Zn   15.4 
Mg   13.7 
RMS deviation for  
 Bond   0.005 Å     
 Angle   1.1o
*The numbers in parentheses are for the highest resolution shell. 
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Table 2.3. Kinetic Parameters of PDE4D2(1-507) and PDE7A1(130-482). 
 KM
cAMP
 
(\M) 
kcatcAMP 
 (S-1)
(kcat/KM)cAMP 
(S-1\M-1)
KMcGMP 
(\M) 
kcatcGMP 
 (S-1)
(kcat/KM)cGMP 
(S-1\M-1)
(kcat/KM)cAMP
(kcat/KM)cGMP
PDE4D2 1.5±0.2 3.9±0.3 2.7±0.4 9.9±1.0×102 5.2±0.8 5.3±0.8×10-2 509 
PDE7A1 0.20±0.03 1.6±0.2 7.9±0.9 3.9±0.7×103 6.8±1.3 1.8±0.5×10-3 4389 
The apparent KM and kcat values were determined from Eadie-Hofstee plots of v0 versus 
v0/[S]. Each value was measured at least three times. Protein concentrations were measured at 
O.D. 280 nm normalized by the extinction coefficients. The extinction coefficients and 
molecular weights were calculated using the program ProtoParam.
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Table 2.4. Interactions of IBMX with PDE7A1.  
Inhibitor atoms        PDE7 atoms          Distance (Å) 
IBMX    O6     ...     Gln413 NE2              3.25 
IBMX    N7     ...     Water 106               2.81  
IBMX    O2     ...     Water  59               2.91  
 
Van der Waals’ contacts: 
Xanthine  N9     Phe416      
 C8 Tyr211, Phe416 
N7     Tyr211, Phe416   
C5     Phe416, Val380     
C4     Phe416 
N3     Phe416 
C2     Phe416 
N1     Phe416, Phe384 
C6     Phe416 
O6     Val380, Phe416, Gln413, 
O2     Phe416     
isopropanyl 
C10    Phe416, Phe384, Ile412,      
 C11 Phe416  
C14    Phe384   
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Table 2.5. Inhibition of PDE4D2 (1-507) and PDE7A1 (130-482) by PDE4 inhibitors.  
 Rolipram (IC50 \M) 
RO-20-1724 
(IC50 \M) 
Zardaverine 
(IC50 \M) 
Etazolate 
(IC50 \M) 
PDE4D2 Wild Type 0.55±0.05 2.9±0.1 0.95±0.15 1.1±0.1 
PDE4D2 Y329S 7.5±1.0 16±1 75±5 2.3±0.2 
PDE 7A1 Wild Type 129±10 245±5 75±8 18 ±1 
PDE 7A1 S373Y 43±3 48 ±2 5.5±0.1 6.3±0.8 
PDE 7A1 S377T 54±6 28±2 53±7 10±1 
PDE 7A1 I412S 53±9 115±5 110±10 16±1 
PDE 7A1 S373Y/I412S 25±1 N/D N/D N/D 
PDE 7A1 S373Y/S377T 23±3 N/D N/D N/D 
PDE 7A1 S377T/I412S 32±4 N/D N/D N/D 
PDE 7A1 S373Y/S377T/I412S 3.6±0.4 5.5±0.5 2.3±0.2 5.2±0.8 
The errors were calculated from two or three times of repeated measurement.  
CHAPTER III 
MULTIPLE CONFORMATIONS OF PHOSPHODIESTERASE-5: IMPLICATIONS 
FOR ENZYME FUNCTION AND DRUG DEVELOPMENT 
 
3.1. Abstract
 Phosphodiesterase-5 (PDE5) is the target for sildenafil, vardenafil, and tadalafil, which 
are drugs for treatment of erectile dysfunction. This chapter describes the crystal structures of 
a fully active catalytic domain of unliganded PDE5A1 and its complexes with sildenafil or 
icarisid II. These structures together with the PDE5A1-IBMX complex show that the H-loop 
(residues 660-683) at the active site of PDE5A1 has four different conformations and 
migrates 7 to 35 Å upon inhibitor binding. In addition, the conformation of sildenafil reported 
herein is significantly different from those in the previous structures of chimerically 
hybridized or almost inactive PDE5. Mutagenesis and kinetic analyses confirm that the 
H-loop is particularly important for substrate recognition.  
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3.2. Introduction 
Inhibitors of PDEs have been widely studied as therapeutics: cardiotonics, vasodilators, 
smooth muscle relaxants, antidepressants, antithrombotics, antiasthmatics, and agents for 
improving cognitive functions such as learning and memory (1-8). Some of the most 
successful examples of this drug class are the PDE5 inhibitors sildenafil (Viagra®), 
vardenafil (Levitra®), and tadalafil (Cialis®) that are drugs for treatment of male erectile 
dysfunction (6). However, side effects such as headache and vision disturbance suggest a need 
for further study of the molecular basis of the selectivity of PDE5 inhibitors (9). 
 
The previous crystal structures of the catalytic domain of the PDE5-inhibitor complexes 
showed two different conformations of sildenafil (10-12). However, it remains unknown 
whether these conformations are biologically relevant because the PDE5 enzyme is either 
almost inactive in one study (10) or a chimeric hybrid in another study (11,12). In addition, 
the crystal structure of the catalytic domain of PDE5A1 in complex with the non-selective 
PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX) showed that the conformation of a 
segment at the active site (the H-loop) is different from the same segment in PDE4 (13) and in 
other PDE5 structures (10-12,14). Herein I  report the structures of the catalytic domains of 
human PDE5A1 in the unliganded state and in complex with inhibitors sildenafil and icarisid 
II (Figure 3.1). These structures, together with that of PDE5A1-IBMX, reveal four different 
conformations of the H-loop. In addition, comparison of this PDE5-sildenafil structure with 
the previously published structures shows significantly different conformations of the 
methylpiperazine portion of sildenafil. These unique features of the PDE5 catalytic domain 
55
and the sildenafil configuration are key considerations for understanding action of sildenafil 
and for development of PDE5 inhibitors. 
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3.3. Experimental procedures 
Protein expression and purification of catalytic domain of PDE5A1 -- The cDNA of the 
catalytic domain of human PDE5A1(residues 535-860) was generated by site-directed 
mutagenesis of the bovine PDE5A cDNA (13). The coding regions for amino acids 535-860 
of PDE5A1 were amplified by PCR and subcloned into the expression vector pET15b. The 
resultant plasmid pET-PDE5A1 was transferred into E. coli strain BL21 (Codonplus) for 
overexpression. The E. coli cell carrying pET-PDE5A1 was grown in LB medium at 37oC to 
absorption A600 = 0.7 and then 0.1 mM isopropyl -D-thiogalactopyranoside was added for 
further growth at 15oC overnight. The E. coli cell was resuspended in ice-cold lysis buffer (20 
mM Tris.HCl, pH 8.0, 15 mM imidazole, 50 mM NaCl, 1 mM Z-mercaptoethanol, plus 
protease inhibitor mixture), homogenized, and centrifuged after lysed by French Press. The 
supernatant was loaded into a Ni-NTA agarose (Qiagen) column equilibrated with lysis 
buffer. The column was washed with lysis buffer and eluted with 150 mM imidazole. Eluted 
PDE5A1 protein was digested by thrombin to cleave out the 6×His tag.  The resulted 
PDE5A1 was loaded into Q-Sepharose ion exchange column and collected in pass-through 
fractions while most of unwanted proteins bound to the column. The partial purified PDE5A1 
proteins was concentrated and further loaded into Sephacryl S300 (Amersham Biosciences) 
size exclusive column (95cM × c2.5cM) and eluted with a buffer of 20 mM Tris.HCl, pH 7.5, 
1 mM Z-mercaptoethanol , 1 mM EDTA and 50 mM NaCl. The catalytic domain of 
PDE5A1(535-860) was eluted at the fraction numbers 53-59 (6.5 mL/fractions), which was 
comparable with molecular weight of a monomer (~38Kd). A typical purification yielded 
over 10 mg PDE5A1 with a purity >95% as determined by SDS/PAGE from a 2-liter cell 
culture.  
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The mutants of PDE5A1 were produced by the standard protocol of site-directed 
mutagenesis (QuikChange site-directed mutagenesis kit (Stratagene)). For the deletion 
mutants of W663-678 and W661-681, four glycine residues were inserted as spacer to 
minimize the disturbance on the three-dimensional structure. Overexpression and purification 
of the mutants used the same protocols as for the wild type protein. 
 
Enzymatic assay -- Enzymatic activity of the isolated catalytic domains of wild type 
PDE5A1 and its deletion mutants was assayed by using 3H-cGMP as substrate in a reaction 
mixture of 20 mM Tris.HCl, pH 7.8, 1.5 mM DTT, 10 mM MgCl2, 3H-cGMP (40000 
cpm/assay) at 24oC for 15 min (15). The reaction was terminated by addition of 0.2 M ZnSO4
and Ba(OH)2. Radioactivity of unreacted 3H-cGMP in the supernatant was measured by a 
liquid scintillation counter. The turnover rate was measured at nine concentrations of cGMP 
and controlled at hydrolysis of 15-40% substrate. Each measurement was repeated three times. 
For measurement of IC50 values, ten concentrations of inhibitors were used at a substrate 
concentration that was tenth of the KM and an enzyme concentration that hydrolyzed 50% of 
substrate. 
 
Crystallization and data collection -- All crystals of PDE5A1 (535-860) were grown by 
vapor diffusion. The protein drop was prepared by mixing 2 µl protein with 2 µl well buffer. 
The unliganded PDE5A1 crystal was grown at room temperature against well buffer of 0.2 M 
MgSO4, 0.1 M Tris.base (pH 8.5), 12% PEG 3350, and 2% ethanol. The PDE5A1-sildenafil 
complex was prepared by mixing 1 mM sildenafil with 15 mg/mL PDE5A1 at 4oC overnight 
and crystallized against a well buffer of 1.0 M sodium citrate, 2.5% ethanol, 0.1 M HEPES 
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pH 7.5 at 4oC. The PDE5A1-icarisid II complex was prepared by mixing 2 mM icarisid II 
with 15 mg/mL protein at 4oC overnight, and crystallized against a well buffer of 0.1 M 
HEPES (pH 7.5), 12% PEG3350 at room temperature.  
 
The unliganded PDE5A1(535-860) was crystallized in the space group P3121 with cell 
dimensions of a = b = 74.7 and c = 130.7 Å. The PDE5A1-sildenafil crystal had the space 
group P6222 with cell dimensions of a = b = 164.6 and c = 193.1 Å. The PDE5A1-icarisid II 
crystal had the space group P6122 with cell dimensions of a = b = 110.7 and c = 106.2 Å. 
Beamline X25 at Brookhaven National Laboratory was used for collection of diffraction data 
of the unliganded PDE5A1, and X29 for PDE5A1-sildenafil and PDE5A1-icarisid II (Table 
3.1). All data were processed by program HKL (16). 
 
Structure determination -- The structure of the unliganded PDE5A1 was solved by 
rigid-body refinement of the PDE5A1 catalytic domain in PDE5A1-IBMX. The structures of 
PDE5A1 in complex with sildenafil and icarisid II were solved by the molecular replacement 
program AMoRe (17), using the PDE5A1-IBMX structure without the H-loop and IBMX as 
the initial model. The rotation and translation searches for the crystal of PDE5A1-icarisid II 
yielded a correlation coefficient of 0.74 and R-factor of 0.31 for 3054 reflections between 4 to 
8 Å resolution. The rotation and translation searches for PDE5A1-sildenafil yielded a 
correlation coefficient of 0.22 and R-factor of 0.52 for 11612 reflections between 4 to 8 Å 
resolution for the first molecule, and of 0.39 and 0.41 after the second molecule was added. 
The electron density map was improved by the density modification package of CCP4 (18). 
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The atomic model was rebuilt by program O (19) and refined by program CNS (Table 3.1, 
20). 
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3.4. Results 
Multiple conformations of the H-loop of PDE5 -- The crystallographic asymmetric units 
contain one molecule of the catalytic domain in the structures of the unliganded PDE5A1 and 
the icarisid II complex, but three molecules in PDE5A1-sildenafil structure. The electron 
density maps showed that the entire catalytic domain in the PDE5A1-icarisid II structure and 
molecule A in the PDE5A1-sildenafil structure were traceable. However, residues 668-676 of 
molecules B and C in the PDE5A1-sildenafil crystal and residues 793-807 in the unliganded 
PDE5A1 lacked electron density and were disordered. The Ramachandran plots showed that 
the backbone conformations of 90-94% residues in the three structures were located in the 
most favored regions and no residues were located in the energetically disallowed regions. 
 
The structures of the catalytic domains of the unliganded PDE5A1 (residues 535-860) 
and its complex with sildenafil or icarisid II consist of 14 common -helices and a variable 
H-loop at the active site (Figure 3.2). Structural superposition of the unliganded PDE5A1 
over the complexes of PDE5A1-IBMX, PDE5A1-sildenafil, and PDE5A1-icarisid II yielded 
RMS deviations of 0.29, 0.42, and 0.54 Å for the C atoms of comparable residues (536-659, 
684-787, and 810-860), respectively, suggesting overall structural similarity. However, the 
H-loop (residues 660-683 on the basis of the structural comparison of 7 PDE families, which 
are slightly different from the previous assignment of residues 661-676 (13)) adopts four 
conformations and different tertiary structures in the crystals of the unliganded PDE5A1 and 
its complexes with IBMX, sildenafil, or icarisid II. In the unliganded PDE5A1 structure, the 
H-loop contains a few turns, but the majority of its residues exist in coil conformation (Figure 
3.2). Binding of IBMX converts the H-loop into two short -helices at residues 664-667 and 
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672-676 (Figure 3.2F) and shifts the C-atoms of the H-loop as much as 7 Å from those in the 
unliganded structure. In the PDE5-sildenafil structure, the H-loop in molecule A is converted 
to a turn and a 310-helix at residues 672-675 and the whole loop migrates as much as 24 Å to 
cover the active site (Figure 3.2). However, the H-loop in molecules B and C are disordered. 
The most dramatic change in the H-loop occurs in the structure of PDE5A1-icarisid II, in 
which the H-loop contains two -strands at residues 662-666 and 675-679 (Figure 3.2F) and 
migrates as much as 35 Å from the position in the unliganded PDE5A1. 
 
To verify that the conformational changes are not due to an artifact of structure 
determination or crystal packing, electron density maps were calculated and lattice 
interactions in the various crystal forms were examined. The maps that were calculated from 
the structure with omission of the H-loop showed solid electron density for almost all residues 
of the H-loops, thus confirming the true conformational variation in the PDE5A1 structures. 
This is supported by the fact that B-factors for the H-loops are comparable with or slightly 
higher than the overall average B-factors for the protein atoms: 48 versus 38 Å2 for the 
unliganded PDE5A1, 61 versus 40 Å2 for PDE5A1-IBMX, 33 versus 33 Å2 for 
PDE5A1-icarisid II, and 38 versus 27 Å2 for PDE5A1-sildenafil. In addition, the following 
facts suggest minor roles of the lattice contacts in the conformational changes of the H-loop. 
First, the unliganded PDE5A1 and its IBMX complex have the same space group and the 
similar unit cell parameters (a = b = 74.7, c = 130.7 Å versus a = b = 74.5, c = 130.1 Å), but 
different H-loop conformations. Second, the PDE4 H-loop in the chimeric PDE5 structure is 
involved in the crystal lattice interactions, but retains its PDE4 conformation (12). Thus, the 
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dramatic conformational changes of the H-loop must be the consequence of binding of the 
specific inhibitors. 
 
In addition to variation of the H-loop, minor conformational differences are observed for 
another active site loop, the M-loop (residues 788-811 on the basis of the structural 
comparison among 7 PDE families, in comparison to the original assignment of residues 
787-812 (13)). Residues 793-807 of the M-loop are not traceable in the structures of the 
unliganded or IBMX-bound PDE5A1. However, the well-ordered M-loops in the structures 
of PDE5A1 in complex with sildenafil or icarisid II contain an extra 310 helix and a 
ten-residue extension of -helix H14, in addition to the correspondence of a 310 helix to the 
N-terminal portion of H15 in the unliganded PDE5A1 (Figure 3.2f). 
 
PDE5 shows an apparently unique feature distinct from other PDE families, although the 
overall topological folding of PDE5A is similar to those of PDE1B (12), PDE2A (21), 
PDE3B (22), PDE4B and PDE4D (12-14, 23-27), PDE7A (15), and PDE9A (28). The core 
catalytic domains of PDE1, 2, 3, 4, 7, and 9 (residues 115-411 in PDE4D2), including the 
H-loop that is composed of two short -helices (H8 and H9, residues 209-215 and 218-222 in 
PDE4D2, Figure 3.2f), have a uniform conformation and are superimposable on one another. 
In contrast, the H-loop of PDE5A1 shows four conformations, and none of these is 
comparable with any of the corresponding H-loops in other PDE families. The closest 
comparable conformation is the H-loop in the PDE5A1-IBMX structure, which also contains 
two short -helices. However, these two helices have as much as 7 Å positional difference 
from those in PDE4D2 (13), and are in a different three-dimensional arrangement. In 
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addition, the -strand components of the H-loop in the PDE5A1-icarisid II complex are 
unique among active sites of known PDE structures. Therefore, the active site of PDE5 
appears to belong to a special category of the PDE superfamily. 
 
Conformation variation of sildenafil -- Sildenafil binds to each active site of three 
PDE5A1 catalytic domains in the crystallographic asymmetric unit with similar conformation 
and occupancy, as shown by the comparable B-factors and the clean electron density in the 
omitted maps (Figure 3.3). The binding of sildenafil causes a dramatic conformational change 
of the H-loop and a movement as much as 24 Å from that in the unliganded PDE5 structure. A 
direct consequence of the H-loop movement is the transformation of the open PDE5A1 active 
site to a closed pocket. Sildenafil is partially buried in the pocket. Solvent accessible surface 
of sildenafil after binding to PDE5A1 is reduced to 9.4% of the total surface area. Sildenafil 
borders the metal-binding pocket, but does not directly interact with the metal ions. The 
pyrazolopyrimidinone group (R1 in Figure 3.1, Table 3.2) of sildenafil stacks against Phe820 
of PDE5A1 and also contacts residues Tyr612, Leu765, Ala767, and Gln817. The O1 and N4 
atoms of pyrazolopyrimidinone form two hydrogen bonds with NE2 and OE1 of Gln817, 
respectively. The ethoxyphenyl group (R2, Figure 3.1) interacts via van der Waals forces with 
Val782, Ala783, Phe786, Leu804, Ile813, Gln817, and Phe820. The methylpiperazine group 
(R3, Figure 3.1) contacts Asn662, Ser663, Tyr664, Ile665, Leu804, and Phe820. The oxygen 
atoms of the sulfate group interact mainly with Phe820. 
 
Our PDE5A1-sildenafil structure is similar in many respects to those reported earlier 
(10-12), as shown by the RMS deviations of 0.59 and 0.40 Å for superposition of the 
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backbone atoms of the comparable residues (without 661-677) of our PDE5A1-sildenafil 
over the two previous structures. However, two significant differences are observed among 
the three PDE5A-sildenafil structures. First, the H-loop in our structure has definite electron 
density and different conformation from those in the previously published structures in which 
the H-loop is either disordered (missing residues 665-675) (10) or takes the PDE4 
conformation due to chimeric replacement of PDE5 residues 658-681 with those of PDE4 
(12). Second, the conformations and the interactions of sildenafil in the three 
PDE5A-sildenafil structures are significantly different. While the ethoxyphenyl and 
pyrazolopyrimidinone groups of sildenafil in the three PDE5A structures are superimposable 
and interact with the same residues of PDE5A, the methylpiperazine shows different 
orientations (Figure 3.3). Methylpiperazine in our PDE5A1-sildenafil structure folds to 
interact with pyrazolopyrimidinone, in comparison with the conformation that extends in a 
different direction in the structure of Sung et al. (10). The conformation of the 
methylpiperazine in the structure of Zhang et al. (12) is similar to ours, but shows a twist of 
about 40o (Figure 3.3).  In addition, the contacts between the methylpiperazine and the H-loop 
residues differ substantially.  In our structure, the methylpiperazine interacts with Asn662, 
Ser663, Tyr664, and Ile665 in the H-loop (Table 3.2).  However, there are no contacts 
between the methylpiperazine and the H-loop in the structure of Zhang et al., and the 
methylpiperazine contacts Tyr664, Met816, Gly819, and Phe820 in the structure by Sung et 
al. 
 
To exclude possible false results from the structure determination, we re-examined the 
three structures of the PDE5A catalytic domain in complex with sildenafil. The (2Fo – Fc) 
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and (Fo – Fc) maps that are calculated from the PDE5A catalytic domains with omission of 
sildenafil show reasonable electron density for all three sildenafils, suggesting their true 
bound conformations in the crystal states. Thus, the basis for the conformational differences 
of sildenafil needs to be explored. The difference in twist of about 40o of the methylpiperazine 
ring may be the consequence of chimeric replacement of the PDE5 H-loop (residues 658-681) 
with the equivalents of PDE4 in the structure of Zhang et al. (12), in which the H-loop takes 
the conformation of PDE4. For the structure of PDE5A-sildenafil of Sung et al. (10), the 
electron density maps show that Cys677 probably forms an intermolecular disulfide bond 
with Cys677 from a neighboring monomer in the PDE5A crystal. Thus, the catalytic domain 
of PDE5A in the structure of Sung et al. (10) physically forms a dimer, in contrast to a 
monomeric form in the PDE5A-sildenafil structures of ours and Zhang et al. (12). The fact 
that the specific activity of the catalytic domain of Sung et al. (19) is only about one 
thousandth of that reported for monomeric PDE5A (29 and this study) suggests that the dimer 
may be either a less active form of PDE5 or a biologically irrelevant artifact.  It is interesting 
to note that the activity of PDE5A was increased 5-10 folds in the presence of reducing agents 
such as dithiothreitol and Z-mercaptoethanol (Figure 3.4). Mutation of Cys677 to aspartic 
acid (corresponding residue in PDE4) resulted in loss of this effect, implying that the 
intermolecular disulfide bond formed by Cys677 involved in the conformation changes of the 
H-loop and therefore affect the enzyme function of PDE5A1.  Although there are 9 cystine 
residues in the catalytic domain of PDE5, most of them except the Cys677 residue are buried 
and no disulfide bond has been reported across all PDE families. Whether the disulfide bond 
observed in the structure of PDE5A-sildenafil of Sung et. al. is biological relevant or not 
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remains unclear. However, it might indicate that the H-loop may be involved in the regulation 
of PDE5 activity. 
Binding of icarisid II to PDE5 -- Icarisid II is a glycoside derivative of flavonoids from 
the plant Epimedium wanshanense that has been used as an herbal medicine for improvement 
of erectile dysfunction in China for more than a thousand years (30-33). Icarisid II inhibits 
PDE5A1 with an IC50 of 2 µM and shows at least 10 fold selectivity against other PDEs. It 
binds to the active site of PDE5A1, as shown by the electron density that is calculated from 
the PDE5A1 structure before icarisid II was built in (Figure 3.5). The binding of icarisid II 
causes formation of two -strands in the H-loop and as much as 35 Å movement of the H-loop 
to completely close the active site (Figures 2e & 4). The solvent accessible area of icarisid II 
after binding to the active site of PDE5A1 is reduced to 0.05% of the unbound form. 
 
Five hydrogen bonds are formed between icarisid II and PDE5A1 residues. The 
oxychromone (R2, Figure 3.1, Table 3.2) of icarisid II stacks against Phe820 and its oxygen 
atoms O4 and O10 form three hydrogen bonds with the backbone nitrogen of Ile665, the side 
chain oxygen of Ser668, and a water molecule. It also interacts with residues Tyr664, Leu725, 
Leu804, and Met816 (Figure 3.5). The methoxyphenyl group (R1, Figure 3.1) forms a 
hydrogen bond with the backbone nitrogen of Ile768 and makes van der Waals contacts with 
Ala767, Ile768, Gln775, Ala779, Gln817, and Phe820 (Table 3.2). The pentenyl group (atoms 
C17-C21, Figure 3.1) forms hydrophobic contacts with Val782, Phe786, Leu804, Met816, 
and Gln817. The rhamnose group (R3, Figure 3.1) forms three hydrogen bonds with NE2 of 
His613, OD2 of Asp764, and a water molecule, in addition to interactions with residues 
Tyr612, His613, Asn661, Ser663, Leu725, Asp764, Leu765, and Phe820 (Table 3.2). A few 
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atoms of rhamnose are located at distance suitable for van der Waals’ contact with both metal 
ions and directly interact with the metal-binding residues such as Asp764. 
 
Although icarisid II and sildenafil occupy the same active site, the detailed interactions 
of the inhibitors are significantly different (Figure 3.5). Sildenafil forms two hydrogen bonds 
with Gln817 and stack against Phe820. However, Gln817 shows about 90o rotation of its side 
chain (Figure 3.5) and forms no hydrogen bond with icarisid II. In addition, the position of 
oxychromone of icarisid II, which stacks against Phe820, is significantly different from the 
pyrazolopyrimidinone of sildenafil. In consideration of the 1000-fold difference in binding 
affinity between sildenafil and icarisid II, the structural data suggest that the hydrogen bond 
with Gln817 and the stacking with Phe820 are two essential components for high affinity 
binding of inhibitors. 
 
A potential role of the H-loop in substrate/inhibitor recognition -- To understand the 
biochemical basis of multiple conformations of the H-loop, two deletion mutants were 
created in the isolated catalytic domain of PDE5A1. The PDE5A1 mutant with deletion of 
residues 663-678 and insertion of four glycines (to minimize disturbance of the structure) 
showed about 10- and 2-fold lower affinity for cGMP and the inhibitors, respectively (Table 
3.3, Figure 3.6). The mutant with deletion of residues 661-681 and insertion of four glycines 
had a 150-fold weaker KM for cGMP and 30-80-fold less potent IC50 for the inhibitors (Table 
3.3). However, both mutants had kcat values comparable with that of the wild type PDE5A1 
catalytic domain. These data imply that the H-loop is less critical for binding of inhibitors 
than for cGMP. This is consistent with the early report that a sildenafil homolog UK-122764 
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that lacks methylpiperazine and thus interactions with the H-loop shows only a 5-fold lower 
potency than sildenafil (34). 
 
The kinetic data indicate that the W663-678 mutant affects KM for cGMP, but have much 
less effect in catalytic turnover rate and inhibitor binding (Table 3.3). Although no 
interactions between the H-loop and the low affinity product GMP were observed in the 
chimeric PDE5-GMP structure (12), it is plausible that the H-loop may contact cGMP in a 
pattern like that of sildenafil or icarisid II. Since hydrolysis of the phosphodiester bond of 
cGMP occurs in the metal-binding subpocket, the distal position of the H-loop from the metal 
site in the structure would be more consistent with its role in substrate binding rather than 
hydrolysis. This would imply a dynamic interplay between the H-loop and substrate, in which 
binding of cGMP and the H-loop conformation would mutually regulate one another. Further 
structural studies will be required to completely define the mechanism involved in the H-loop 
modulation of substrate affinity and inhibitor binding. 
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3.5. Discussion 
Extensive studies on the crystal structures of PDEs have shown that the PDE families 
have similar three-dimensional structures for their isolated catalytic domains and active sites 
(19-24, 31-38). However, information on the conformation of the PDE5 active site and on 
sildenafil binding is incomplete because early studies showed a disordered or artificially 
replaced H-loop at the active site (10-12). The present study, in combination with the 
PDE5A1-IBMX structure (13), reveals that the H-loop of PDE5 can adopt four clearly 
defined conformations. These different conformations of the H-loop of PDE5 may be the 
result of direct contacts between the H-loop and inhibitors, such as those in the structures of 
PDE5A1 in complex with sildenafil or icarisid II. Alternatively, the H-loop changes may be 
imposed by more distant effects of conformational changes following inhibitor occupation of 
the binding pocket, as implicated by no direct contacts between the H-loop and IBMX. 
Finally, a combination of both direct and indirect interactions may contribute to the H-loop 
changes. Since all other PDEs appear to have a similar conformation of the H-loop that is not 
comparable with any of the conformations of the PDE5 H-loop, the PDE5 active site 
apparently has a unique structural characteristic. The mutual communication between 
inhibitor binding and conformational changes of the PDE5 catalytic pocket may thus be 
valuable for design of new inhibitors with unique selectivity against PDE5.  
 
It is common that an inhibitor slightly adjusts its conformation to provide an optimal fit 
in the binding pocket of a protein. However, the conformational variation of sildenafil in the 
different crystal forms, as seen in the significantly different conformations of the 
methylpiperazine group is unusual. Since inhibitors are commonly designed to mimic 
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contacts employed by the substrate, the dramatic effect of the H-loop mutations on affinity for 
cGMP and the flexibility of sildenafil provide potentially important direction in development 
of new PDE5 inhibitors.  
 
Side effects such as vision disturbance of patients after ingestion of PDE5 inhibitors (9) 
dictate a need for detailed study of the molecular basis for the action of these drugs and 
development of new potential inhibitors. Derivatives of flavonoids may be such a new 
category of PDE5 inhibitors. Flavonoids inhibit PDEs with affinity at the micromolar level 
and slight selectivity (35,36), and are widely used as dietary supplements that have reached a 
multiple billion dollar business (37-39). In the present report, the structure of 
PDE5A1-icarisid II shows how this natural dietary compound interacts with PDE5 and thus 
provides a valuable guideline for development of a new category of PDE5 inhibitors. 
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Figure 3.1. Chemical structures of PDE5 inhibitors. The letters R1-R3 label the main groups in 
sildenafil and icarisid II. In sildenafil, R1 represents the pyrazolopyrimidinone group, R2 is 
ethoxyphenyl, and R3 is methylpiperazine. In icarisid II, R1 represents the methoxyphenyl 
group, R2 is oxychromone, and R3 is rhamnose. 
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Figure 3.2. Structures of PDE5 and its inhibitor complexes. (A) Ribbon diagram. The cyan 
ribbons are the common structures of the catalytic domains of unliganded PDE5A1 and its 
complexes. The different conformations of the H-loop in the four structures are shown in 
colors of purple for the unliganded PDE5A1, blue for the IBMX complex, golden for the 
sildenafil complex, and green for the icarisid II complex. Zn is colored red and Mg is purple. 
(B)-(E) Surface presentation for the unliganded PDE5A1 catalytic domain (B), 
PDE5A1-IBMX (C), PDE5A1-sildenafil (D), and PDE5A1-icarisid II (E). The middle red 
pocket is the active site. The inhibitors are shown in color balls: blue for IBMX, golden for 
sildenafil, and green for icarisid II. Icarisid II is almost completely buried and the orientation 
of the domain is adjusted to show up the icarisid II binding. (F) The alignment of the 
secondary structures with the amino acid sequence around the regions of the H- and M-loops 
that are shown in bold letters. The symbol represents 310 helix;        is for Z strand; and                                                                                                                                                                  
is for d-helix. The dots represent disordered regions in the unliganded and IBMX-bound 
PDE5. 
 
(A)
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pde4d2   187 DLEILAAIFA SAIHDVDHPG VSNQFLINTN SELALMYNDS SVLENHHLAV 236 
pde5a1   640 DLEILALLIA ALSHDLDHRG VNNSYIQRSE HPLAQLY-CH SIMEHHHFDQ 688 
Unliganded 
IBMX                                            
Sildenafil                                        
Icarisid II  
 
pde4d2   327 QLYRQWTDRI MEEFFRQGDR ERERGMEIS- -PMCDKHNAS VEKSQVGFID 374 
pde5a1   773 PIQQRIAELV ATEFFDQGDR ERKELNIEPT DLMNREKKNK IPSMQVGFID 822 
Unliganded                        ................. 
IBMX                              .................         
Sildenafil                                        
Icarisid II 
(F)
H7
H7
H7
H7
H7
H8 H9 H10
H10
H10
H10
H10
H15
H15
H15
H14 H15
H14
H14
H14
H14
H15
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Figure 3.3. Sildenafil binding. (A) Stereoview of electron density for sildenafil bound to 
PDE5A1. The (2Fo-Fc) maps was calculated from the structure omitting sildenafil and 
contoured at 1.5. (B). Interactions of sildenafil (golden stick-balls) with the active site 
residues (green sticks). The dotted lines represent hydrogen bonds. (C) Superposition of 
sildenafils from the PDE5A1-sildenafil structures of Zhang et al. (12, golden), Sung et al. (10, 
cyan), and ours (green). 
 
(A) 
 
(B)                                                             (C)
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Figure 3.4. Effects of reducing agent on the activity of PDE5A. (A) The activity of PDE5A 
was increased 5-10 folds in the presence of  reducing agents such as dithiothreitol and 
Z-mercaptoethanol. (B) Mutation of Cys677 to aspartic acid (corresponding residue in PDE4) 
caused the loss of this effect. Specific activity was measured under the substrate concentration 
of 0.2 µM cGMP. 
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Figure 3.5. Icarisid II binding. (A) Stereoview of electron density for icarisid II bound to 
PDE5A1. The (2Fo-Fc) maps were calculated from the structure before icarisid II was built in 
and contoured at 1.5. (B) Interaction of icarisid II (golden sticks-balls) with the PDE5A1 
residues (green sticks) at the active site of PDE5A1. The dotted lines represent hydrogen 
bonds. (C) Superposition of icarisid II (golden sticks) and sildenafil (purple ball-sticks). 
Residues from PDE5A-sildenafil are shown in blue and residues from the icarisid II complex 
is drawn in green. 
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Figure 3.6. Inhibition of the isolated PDE5 catalytic domain of wild type and H-loop deletion 
mutants by IBMX, icarisid II, and sildenafil.  
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Table 3.1.  Statistics on diffraction data and structure refinement. 
Data collection  PDE5A1 native PDE5A1-sildenafil
 PDE5A1-Icarisid II  
Space group   P3121   P6222   P6122 
Unit cell (a, b, c, Å)  74.7, 74.7, 130.7 164.6, 164.6, 193.1 110.7, 110.7, 
106.2 
Resolution (Å)  1.85   2.3   1.8 
Total measurements  363,960  1,121,219  412,999 
Unique reflections    36,603  68,786    36,177 
Completeness (%)  99.5 (100.0)*  99.9 (100.0)  99.9 (99.7) 
Average I/ 20.8 (7.4)*  6.7 (4.8)  13.6 (4.3) 
Rmerge   0.058 (0.49)*  0.117 (0.58)  0.061 (0.46) 
 
Structure Refinement 
R-factor   0.221   0.210   0.206 
R-free    0.236 (9.7%)‡  0.246 (9.7%)  0.233 (9.7%)  
Resolution (Å)  15-1.85  48-2.3   44-1.8 
Reflections   34,996   66,315   35,094 
RMS deviation for  
Bond    0.0078 Å  0.0061   0.0073 
Angle    1.25o 1.17o 1.31o
Average B-factor (Å2)
Protein   37.5 (2523)§  27.8 (7804)  27.9 (2650)  
 Inhibitor     29.4 (99)  25.9 (37) 
 Waters   37.9 (148) §  28.8 (311)  32.8 (231)  
 Zn   46.2 (1)§   44.9 (3)  36.6 (1) 
 Mg   33.4 (1)§   37.6 (3)  41.0 (1) 
 
*The numbers in parentheses are for the highest resolution shell. 
‡The percentage of reflections omitted for calculation of R-free. 
§The number of atoms in the crystallographic asymmetric unit. 
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Table 3.2. Interactions of sildenafil and icarisid II with PDE5A.  
Inhibitor   atoms  PDE5 atoms  Distance (Å) 
Sildenafil   N4    Gln817 OE1      2.9 
 O2 Gln817 OE1      3.2 
 O1 Gln817 NE2      3.2 
 O1 H2O 2.7
N1       H2O 2.6
Icarisid II  O1    Ile768 N        3.1 
 O4 Ile665 N        2.8 
 O10 Ser668 OG       3.0 
 O7 His613 NE2      2.7 
 O8 Asp764 OD2      2.8 
 O8 H2O 2.6
O10      H2O 2.7
Van der Waals’ contacts: 
For sildenafil 
Pyrazolopyrimidinone   Tyr612, Leu765, Ala767, Val782, 
Gln817, Phe820     
Ethoxyphenyl              Val782, Ala783, Phe786, Leu804, Ile813, 
Gln817, Phe820    
methylpiperazine       Asn662, Ser663, Tyr664, Ile665, Leu804, 
Phe820
For icarisid II 
Methoxyphenyl         Ala767, Ile768, Gln775, Ala779, Val782, 
Gln817, Phe820    
Oxychromone            Tyr664, Ile665, Ser668, Leu725, Leu804, 
Met816, Phe820 
Pentenyl            Val782, Phe786, Leu804, Met816, Gln817    
Rhamnose   Tyr612, His613, Asn661, Ser663, Leu725, 
Asp764, Leu765,Phe786, Phe820 
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Table 3.3.  Kinetic properties of PDE5A1 isolated catalytic domain and its mutants. 
 
Wild type 
KM cGMP 
(\M) 
5.1±1.3 
kcatcGMP 
 (sec-1)
1.3±0.3 
(kcat/ KM)cGMP 
(s-1\M-1)
0.27±0.08 
IBMX 
(IC50 \M) 
2.1±0.5 
Icarisid II 
(IC50 \M) 
1.7±0.4 
Sildenafil 
(IC50 nM) 
2.4±0.3 
W(663-678)* 54±6 3.8±0.5 0.07±0.013 5.3±1.1 2.5±0.2 5.9±1.5 
W(661-681)* 750±210 2.3±0.6 0.0031±0.0002 95±6 55±13 188±29 
*Four glycines were inserted as a linker. Each of the experiments was repeated three times. 
 
CHAPTER IV 
CRYSTAL STRUCTURES OF PDE10 IN COMPLEX WITH SUBSTRATES AND 
PDE4 SUBFAMILIES IN COMPLEX WITH A PDE4D-SELECTIVE INHIBITOR 
 
4.1. Introduction  
Structural studies on PDEs have been challenging because of difficulty in preparation of soluble 
PDE proteins. Most research groups expressed PDE proteins in insect cells. However, due to the low 
expression level of baculovirus systems, a large scale of purification for crystallographic study is a 
disadvantage for academic groups. Several groups purified PDEs by refolding or expressed PDEs 
using in vitro translation system (1,2). I have focused on expression of PDEs in E. coli and succeeded 
in purification of the catalytic domains of PDE2A3, PDE3A, PDE4 subfamilies A to D, PDE5A1, 
PDE7A1, PDE9A2, and PDE10A2. This chapter describes the recent progress on the crystal 
structures of PDE10A catalytic domain and its complex with cAMP and cGMP, and crystallization 
trials on the PDE4 subfamily members in complex with a PDE4D selective inhibitor. 
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4.2. Crystal structure of PDE10 
Phosphodiesterase family 10 (PDE10) is mostly expressed in testis and brain (3-5). 
PDE10 contains two GAF domains preceded its catalytic domain. PDE10A hydrolyzes 
cGMP with a KM of 3-7.2 µM and cAMP with a KM of 0.05-0.26 µM (3-5), thus exhibiting 
dual-substrate selectivity. Up to date, neither crystal structures nor selective inhibitors of 
PDE10 have been reported. Therefore, substrate specificity and inhibitor selectivity of the 
PDE10 family remain unknown. Here, I report the crystal structure of the catalytic domain of 
PDE10A2 and the preparation of inactive D764A mutant of PDE10A catalytic domain. 
Crystals of the inactive PDE10A mutant in complex with both substrates of cAMP and cGMP 
are in progress. Since no structures of PDE families in complex with substrates or their 
analogs have been reported, these structures will not only provide insight into substrate 
specificity, but may also serve as templates for development of selective inhibitors of PDE10. 
 
Expression, purification and crystallization of PDE10A2--The cDNA clone of human 
PDE10A2 (AB026816) was purchased from ATCC (IMAGE: 6106131). The catalytic 
domain of PDE10A2 (residues 448-789) was subcloned into vector pET15b. The E. coli cell 
carrying pET-PDE10A2 was grown in 2xYT medium at 37oC to absorption A600 = 0.7 and 
then 0.1 mM isopropyl -D-thiogalactopyranoside was added for further growth at 20oC
overnight. The E. coli cell was resuspended in ice-cold lysis buffer (20 mM Tris.HCl, pH 8.0, 
15 mM imidazole, 50 mM NaCl, 1 mM Z-mercaptoethanol, plus protease inhibitor mixture), 
centrifuged after lysed by French Press. The supernatant was loaded into a Ni-NTA agarose 
(Qiagen) column and eluted with 150 mM imidazole. Eluted PDE10A2 protein was digested 
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by thrombin to cleave out the 6×His tag.  The resulted PDE10A2 was loaded into 
Q-Sepharose ion exchange column and eluted with 20 mM Tris.HCl, pH 7.5, 1 mM 
Z-mercaptoethanol , 1 mM EDTA and 100 mM NaCl.  The partial purified PDE10A2 proteins 
was concentrated and further loaded into Sephacryl S300 (Amersham Biosciences) size 
exclusive column (95cM × c2.5cM) and eluted with a buffer of 20 mM Tris.HCl, pH 7.5, 1 
mM Z-mercaptoethanol , 1 mM EDTA and 50 mM NaCl. The catalytic domain of 
PDE10A2(448-789) was eluted at the fraction numbers 53-59 (6.5 mL/fractions), which was 
comparable with molecular weight of a monomer(~39Kd). The PDE10A2 protein had purity 
greater than 95% as shown by SDS-PAGE. A typical batch of purification yielded over 10 mg 
PDE10A2 from a 2-liter cell culture.  
 
The mutant PDE10A2(448-789)D674A were produced by the standard protocol of 
site-directed mutagenesis (QuikChange site-directed mutagenesis kit (Stratagene)). 
Overexpression and purification of the mutant PDE10A2 were used the same protocols as for 
the wild type protein.  
 
The catalytic domain of PDE10A2 and its mutant was crystallized by hanging drop at 
4oC.  The protein drops contained 2 µl of 7 mg/ml PDE10A2 and 2 µl well buffer of 0.1 M 
HEPES (pH 7.5), 0.1-0.2 M MgCl2, 25-200 mM Z-mercaptoethanol and 10-20% PEG 3350. 
The PDE10A2 crystal diffracts to 2.2 Å resolution in our RAXIS4++ system with a 
cryosolvent 0.1 M HEPES (pH 7.5), 0.1 M MgCl2, 25 mM Z-mercaptoethanol, 20% PEG 
3350 and 20% Ethylene Glycol. The crystal has the space group P212121 with a =51.1, b 
=82.1, and c = 155.2 Å. The structure of PDE10 was determined by molecular replacement 
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program AmoRe (6), using the catalytic domain of PDE5A as the searching model. The 
structure was refined by program CNS (7) to R-factor/R-free of 0.22/0.27 at 2.2 Å resolution 
(Table 4.1). The crystal of the mutant PDE10A2(448-789)D674A has a space group P212121
with a =51.4, b =82.1, and c = 155.3 Å. For PDE10A/cAMP or PDE10A/cGMP complexes, 
the crystal of the mutant was soaked with 20-50 mM cAMP or cGMP at 4oC or 25oC for 1-8 
hours with a soaking buffer 15% PEG8000, 0.06 M HEPES (pH 7.5), 0.06 M MgCl2, 30 mM 
Z-mercaptoethanol, 30 mM NaCl, 12 mM Tris-HCl (pH 7.5), 0.6 mM EDTA. The 
cryosolvent is similar with the soaking buffer in addition to 20% PEG400. 
 
Results and discussion--The crystal of the PDE10A2 catalytic domain contains two 
protein molecules per asymmetric unit. The crystal packing shows that the catalytic domain of 
PDE10A2 is a dimmer (Figure 4.1). The catalytic domain of PDE10A2 is composed of fifteen 
d-helices and five 310 helices. The overall folding of the catalytic domain of PDE10, except 
for the N-terminus, is similar to those of other seven PDE families whose structures are 
known. The variation of the N-termini in the catalytic domains of PDEs possibly reflects 
structural differences across PDE families. In PDE10, the corresponding residues of the 
H-loop in PDE5 adopt two d-helices, which is similar to PDE4, consistent with that the 
H-loop in PDE5 is unique across all known structures of the catalytic domain of PDEs (Figure 
1.6). Further structure analysis is in progress.  
 
Because PDEs present a kcat value around 1 sec-1, the time scale of crystallization as well 
as soaking will be enough for PDEs to hydrolyze the substrate completely. Therefore, only 
PDEs in complex with a product have been reported (8, 9). To achieve a complex structure of 
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a PDE with the substrate cAMP or cGMP, I mutated a residue D674A in PDE10A2, which is 
responsible for binding of a metal ion and for hydrolysis of substrates, but expected to play 
little role in substrate binding (8, 9).  The mutant PDE10A2 has a specific activity 
3.2±0.5×10-5 µmol/min/mg for cAMP, which is about 1.5×104 less than wild type (0.48±0.01 
µmol/min/mg). The crystal of the mutant PDE10A2 was soaked with cAMP and cGMP and 
the ligand binding has been observed. We are planning to collect higher quality data on a 
synchrotron source.  
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4.3. Studies on subfamily selectivity of PDE4 inhibitors 
PDE4 inhibitors have shown great potential for treatment of asthma and chronic 
obstructive pulmonary disease (10-16), but side effects such as emesis are the main obstacles 
for PDE4 inhibitors to be drugs used in practical treatment. While mechanisms for the side 
effects are not clear, selective inhibition on one of four subfamilies of PDE4 has become the 
current focus of PDE4 inhibitor development (11-13, 17). However, only a few subtype 
selective PDE4 inhibitors have been reported (18) and no structures of PDE4 in complex with 
subfamily selective inhibitors are available, thus leaving subfamily selectivity as a veiled 
puzzle. Absolute conservation of the rolipram binding residues in the PDE4 subfamilies 
suggests that the subfamily selectivity is largely dependent on the conformational states of the 
PDE4 subfamilies. To elucidate the basis of PDE4 subfamily selectivity and to provide 
templates for design of PDE4 subfamily specific inhibitors, I target to determine the 
structures of PDE4 subfamilies (A, B, C, and D) in complex with a PDE4 subfamily selective 
inhibitor. Herein, I describe the preliminary processes on expression of the catalytic domains 
of PDE4 subfamilies A to D and crystallization of PDE4A-D in complex with a PDE4D 
subfamily inhibitor. 
 
Expression and purification of PDE4A, PDE4B, PDE4C and PDE4D--There exist the 
protocols for overexpression of the catalytic domain of PDE4B and PDE4D2 in Dr. Ke’s lab. 
I reconstructed PDE4B and PDE4D2 to obtained crystals that diffract to higher resolution. 
The cDNA clone of human PDE4A10 (BF528806) was purchased from ATCC. The cDNA 
clone of human PDE4C2 was provided by Dr. Miles Houslay at University of Glasgow, UK. 
The catalytic domains of PDE4A10 (residues 290-622), PDE4B (residues 152-487), PDE4C2 
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(residues 200-558), and PDE4D2 (residues 86-413) were cloned into the expression vector 
pET15b, following the standard methods. The plasmids of pET-PDE4A10, pET-PDE4B2B, 
pET-PDE4C2, and PDE4D2 were transferred into E. coli strain BL21 (Codonplus) and 
expressed in LB medium at 11oC-15oC for 20-38 hours. The recombinant PDE4A10, 
PDE4B2B, PDE4C2, and PDE4D2 were purified by the columns of Ni-NTA agarose, 
Q-sepharose, and Sephacryl S300. A typical batch of purification from a 2 liter cell culture 
yielded 10 mg PDE4A10, 20 mg PDE4B, 15 mg PDE4C2, and 50 mg PDE4D . The purified 
proteins have a purity of >95%. 
 
Crystallization of PDE4A-4D in complex with PDE4D subfamily selective inhibitors 
--Novartis’ inhibitor NVP-ABE171 (4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine- 
6-yl)-benzoic acid, Figure 4) is the best PDE4 subfamily-selective inhibitor and has IC50 
values of 602, 34, 1230, and 1.5 nM for PDE4A, 4B, 4C, and 4D (23). Crystals of the catalytic 
domains of PDE4A, PDE4B, PDE4C, and PDE4D in complex with NVP-ABE171 have been 
grown by hanging drop. The complexes were prepared by mixing 70 mg/ml PDE4A10 
(290-622), 10 mg/ml PDE4B2B (152-487), 15 mg/ml PDE4C2 (200-538), or 12 mg/ml 
PDE4D2 with 2-3.5 mM NVP-ABE171. The following well buffers were used for 
crystallization: 12% PEG400, 200 mM Mg acetate, 0.1 HEPES pH 7.5, 5% glycerol for 
PDE4A10; 10-15% PEG3350, 0.1 HEPES pH 7.5, 30% ethylene glycol, 20% isopropanol at 
4oC for PDE4B2B, 10-15% PEG3350, 100 mM MgCl2, 0.1 HEPES pH 7.5 at room 
temperature for PDE4C2; and 18-22% PEG3350, 0.1 HEPES pH 7.5, 30% ethylene glycol, 
10% isopropanol, 200 mM MgCl2 at 4oC for PDE4D2. The PDE4A10 crystals have the space 
group P41212 with a = b = 105 and c = 164 Å and diffracted to 2.6 Å resolution in our Raxis 
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IV++ system. The PDE4B2B crystals have a space group P43212 with a=b=54 and c=237 Å 
and diffracted up to 2.0 Å. The PDE4C2 crystals have a hexagonal system with a = b = 74 and 
c = 272 Å and diffracted to 3.2 Å resolution in our Raxis IV++ system. The PDE4D2 crystals 
have the space group of P212121 with a = 59, b = 82, c = 162 Å, and diffracted to 2.0 Å 
resolution in our Raxis IV++ system. Improvement of crystallization conditions are in 
progress. We plan to collect higher resolution data of PDE4A, 4B, 4C and 4D in complex 
with NVP-ABE171 on a synchrotron beam line. 
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Figure 4.1. Ribbon diagram of the catalytic domain of PDE10A. The crystal packing shows 
that the catalytic domain of PDE10A2 is dimmer. Zn is colored blue and Mg is yellow.  
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Figure 4.2. Chemical structure of a PDE4D-selective inhibitor NVP-ABE171. The IC50 
values are 602 nM, 34 nM, 1230 nM and 1.5 nM for PDE4A, B, C and D, respectively. 
NN
OH
O
N
ON
NVP-ABE171  
96
 
Table 4.1. Statistics on diffraction data and structure refinement of PDE10A2(448-789). 
Space group       P212121
Unit cell (a, b, c, Å)                 51.1, 82.1, 155.2 
Resolution (Å)                 2.2    
Total measurements                 130,805 
Unique reflections                 31,826  
Completeness (%)                 89.3 (62.3) 
Average I/ 4.2(2.6)*  
Rmerge       0.108(0.469)*   
 
Structure Refinement 
R-factor       0.215    
R-free                                          0.271 (9.0%)‡    
Resolution (Å)                            99-2.2   
Reflections       30,263   
RMS deviation for  
Bond        0.0063Å  
Angle        1.21o
Average B-factor (Å2)
Protein       27.5(5244)§   
 Waters       24.7(192) §    
 Zn       29.6 (2)§    
 Mg       22.6 (2)§    
*The numbers in parentheses are for the highest resolution shell. 
‡The percentage of reflections omitted for calculation of R-free. 
§The number of atoms in the crystallographic asymmetric unit. 
 
CHAPTER V 
OTHER WORKS I CONTRIBUTED TO 
 
Listed as follows are my contributions to other work that has been published. 
 
1. The PDE4D2 structure in complex with enantiomer inhibitors. Huai Q, Sun Y, Wang 
H, Macdonald D, Aspiotis R, Robinson H, Huang Z, Ke H. Enantiomer Discrimination 
Illustrated by the High Resolution Crystal Structures of Type 4 Phosphodiesterase.J Med 
Chem. 49(6):1867-1873.  
 
2. The structure of E coli hsp90. Huai, Q., Wang, H., Liu, Y., Kim, H. Y., Toft, D., and Ke, 
H. (2005) Structures of the N-terminal and middle domains of E. coli Hsp90 and 
conformation changes upon ADP binding. Structure 13, 579-590. 
 
3. The PDE9 structure. Huai, Q., Wang, H., Zhang, W., Colman, R., Robinson, H., and Ke, 
H. (2004) Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 
3-isobutyl-1-methylxanthine binding. Proc. Natl. Acad. Sci. USA, 101, 9624-9629. 
 
4. The DJ-1 structure. Huai, Q., Sun, Y., Wang, H., Chin, L. S., Li, L., Robinson, H., and 
Ke, H. (2003) Crystal structure of DJ-1/RS and implication on familial Parkinson’s disease. 
FEBS Lett. 549, 171-175. 
98
5. The PDE4D2 structure in complex with inhibitor rolipram. Huai, Q., Wang H., Sun, 
Y., Kim, H.Y., Liu, Y., and Ke, H. (2003) Three dimensional structures of PDE4D in 
complex with roliprams and implication on inhibitor selectivity. Structure 11, 865-873. 
 
6. The crystal structure of a complex involving a mouse TCR and a human MHC 
molecule. Buslepp, J., Wang, H., Biddison WE, Appella, E. and Collins, E.J. (2003) A 
correlation between TCR Valpha docking on MHC and CD8 dependence: implications for T 
cell selection. Immunity 19:595-606. 
